Regency Capital Management Inc. DE Sells 3,169 Shares of Danaher Co. (NYSE:DHR)

Regency Capital Management Inc. DE decreased its position in shares of Danaher Co. (NYSE:DHR) by 14.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 18,582 shares of the conglomerate’s stock after selling 3,169 shares during the quarter. Danaher comprises approximately 2.3% of Regency Capital Management Inc. DE’s investment portfolio, making the stock its 19th biggest holding. Regency Capital Management Inc. DE’s holdings in Danaher were worth $4,265,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Jamison Private Wealth Management Inc. boosted its position in shares of Danaher by 1.7% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 9,756 shares of the conglomerate’s stock worth $2,239,000 after purchasing an additional 159 shares in the last quarter. First Citizens Bank & Trust Co. lifted its holdings in Danaher by 1.4% during the fourth quarter. First Citizens Bank & Trust Co. now owns 40,422 shares of the conglomerate’s stock worth $9,279,000 after acquiring an additional 561 shares in the last quarter. Investment Research & Advisory Group Inc. grew its stake in Danaher by 3.4% in the fourth quarter. Investment Research & Advisory Group Inc. now owns 5,338 shares of the conglomerate’s stock valued at $1,225,000 after acquiring an additional 177 shares during the period. Duncan Williams Asset Management LLC increased its holdings in shares of Danaher by 7.2% in the fourth quarter. Duncan Williams Asset Management LLC now owns 4,477 shares of the conglomerate’s stock worth $1,028,000 after acquiring an additional 301 shares in the last quarter. Finally, Affiance Financial LLC raised its position in shares of Danaher by 54.4% during the fourth quarter. Affiance Financial LLC now owns 1,135 shares of the conglomerate’s stock worth $169,000 after purchasing an additional 400 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR opened at $245.95 on Friday. The company has a 50-day simple moving average of $235.33 and a two-hundred day simple moving average of $253.45. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $177.65 billion, a PE ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a one year low of $225.42 and a one year high of $281.70.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is 20.61%.

Analyst Upgrades and Downgrades

Several brokerages have commented on DHR. Stephens restated an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. Evercore ISI upped their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target on the stock. Finally, Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.